Polygenic Risk Score Translation Across Diverse Populations

• by Krieger, Jose E

• June 8, 2026

Investigational Drug Shows Potentialin Phase 3 Obesity Trial

In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.

• by Andrea Surnit

• June 10, 2026

• 4 min

Association between region-specific epicardial adipose tissue and CT-derived fractional flow reserve-defined myocardial ischemia: a retrospective coronary CTA study stratified by hypertension and type 2 diabetes mellitus

• by Zheng Wang, Yunting Hu, Zuoqin Li, Xiang Wang

• June 17, 2026

Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience

• by Mert Tokcan, Franciska Diana Wolter, Mathias Hohl, Peter Fries, Thorsten Kessler, Saarraaken Kulenthiran, Michael Böhm

• June 3, 2026